Approaches to Initiating and Adjusting Luspatercept Dosing

Clinicians discuss personalized approaches to initiating and adjusting luspatercept dosing, considering individual patient responses and tolerability, while also examining insights from the MAXILUS study, which explored starting treatment at the maximum approved dose.

EP: 1.Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

EP: 2.Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

EP: 3.The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

EP: 4.Impact of Improved Hemoglobin Levels on Patient Well-being and Quality of Life

Now Viewing

EP: 5.Approaches to Initiating and Adjusting Luspatercept Dosing

EP: 6.Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

EP: 7.Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

EP: 8.Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents

Video content above is prompted by the following question(s):

• Please share your approach to initiating and adjusting luspatercept dosing based on individual patients’ responses and tolerability?
• Please discuss the MAXILUS study starting luspatercept at the maximum approved dose.

Recent Videos